Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/10/2019 | 06:34am EST

POXEL SA (Euronext POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH) and Sumitomo Dainippon Pharma Co., Ltd (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE), announced today positive top-line Phase 3 data results for the Imeglimin TIMES 1 trial for the treatment of type 2 diabetes in Japan. Referred to as TIMES ( T rials of IM eglimin for E fficacy and S afety), the Imeglimin Phase 3 program in Japan includes three pivotal trials to evaluate Imeglimins efficacy and safety in over 1,100 patients.

I am very excited to contribute to the development of a new and innovative potential treatment option for Japanese patients with type 2 diabetes, said Professor Kohjiro Ueki, MD, PhD, Director, Diabetes Research Center, the National Center for Global Health and Medicine, Tokyo, Japan. Imeglimins safety profile combined with its unique mechanism of action that targets very important deficiencies occurring in diabetes, namely beta-cell function, as well as insulin resistance, could be helpful for Japanese patients to manage their disease.

The TIMES 1 randomized, double-blind, placebo-controlled monotherapy trial orally administered 1,000 mg of Imeglimin twice-daily versus placebo for 24 weeks in 213 Japanese patients. The TIMES 1 trial demonstrated robust efficacy and achieved statistical significance (p

(c) International 2006-2019, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
POXEL 0.81% 7.5 Real-time Quote.47.35%
SUMITOMO CHEMICAL COMPANY, LIMITED -1.96% 499 End-of-day quote.-2.35%
SUMITOMO DAINIPPON PHARMA CO., LTD. 1.58% 2185 End-of-day quote.-35.64%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on POXEL
12/02POXEL : Announces Updates to its Management Team
AQ
11/27POXEL : Announces Positive Topline Results for Imeglimin Phase 3 Trial for the T..
AQ
10/07POXEL : 3rd quarter earnings
CO
09/18POXEL : Initiates Phase 1b Multiple Ascending Dose Trial for NASH Drug Candidate..
AQ
08/26POXEL : Half-year results
CO
08/06POXEL : Initiates Pharmacokinetic Pharmacodynamic Study as part of the Phase 2a ..
AQ
07/15GLOBAL MARKETS LIVE : Facebook, Gilead, AB Inbev, Boeing…
07/15POXEL : 2nd quarter earnings
CO
06/30POXEL : Half-year report
CO
06/26Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results..
AQ
More news
Financials (EUR)
Sales 2019 35,0 M
EBIT 2019 -19,8 M
Net income 2019 -20,0 M
Finance 2019 25,3 M
Yield 2019 -
P/E ratio 2019 -9,58x
P/E ratio 2020 -5,38x
EV / Sales2019 4,82x
EV / Sales2020 7,32x
Capitalization 194 M
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 15,13  €
Last Close Price 7,50  €
Spread / Highest target 127%
Spread / Average Target 102%
Spread / Lowest Target 82,7%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Anne Renevot Chief Financial Officer
Sophie Hallakou-Bozec Senior Vice Chairman-Research & Development
Takashi Kaneko Vice President-Medical
Sector and Competitors
1st jan.Capitalization (M$)
POXEL47.35%214
GILEAD SCIENCES7.24%84 866
VERTEX PHARMACEUTICALS34.72%57 409
REGENERON PHARMACEUTICALS-0.33%40 697
WUXI APPTEC CO., LTD.74.02%21 510
GENMAB51.29%15 541